JP2023534951A5 - - Google Patents
Info
- Publication number
- JP2023534951A5 JP2023534951A5 JP2023502828A JP2023502828A JP2023534951A5 JP 2023534951 A5 JP2023534951 A5 JP 2023534951A5 JP 2023502828 A JP2023502828 A JP 2023502828A JP 2023502828 A JP2023502828 A JP 2023502828A JP 2023534951 A5 JP2023534951 A5 JP 2023534951A5
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- nucleotide
- nucleotides
- group
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052811P | 2020-07-16 | 2020-07-16 | |
| US63/052,811 | 2020-07-16 | ||
| PCT/US2021/041946 WO2022016043A1 (en) | 2020-07-16 | 2021-07-16 | Conjugated oligonucleotides for tissue specific delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534951A JP2023534951A (ja) | 2023-08-15 |
| JP2023534951A5 true JP2023534951A5 (https=) | 2024-07-25 |
Family
ID=79554340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023502828A Pending JP2023534951A (ja) | 2020-07-16 | 2021-07-16 | 組織特異的送達のためのコンジュゲートされたオリゴヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220042015A1 (https=) |
| EP (1) | EP4181932A4 (https=) |
| JP (1) | JP2023534951A (https=) |
| CN (1) | CN116600817A (https=) |
| AU (1) | AU2021308657A1 (https=) |
| CA (1) | CA3174068A1 (https=) |
| WO (1) | WO2022016043A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3033368A1 (en) * | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| US12366070B2 (en) | 2021-04-23 | 2025-07-22 | Stephen Cochran | Cover for circular-profile downspouts having protection from animal/insect intrusion and damage/debris accumulation |
| US20240084301A1 (en) | 2022-07-25 | 2024-03-14 | Amgen Inc. | Rnai constructs and methods for inhibiting fam13a expression |
| WO2024040041A1 (en) * | 2022-08-15 | 2024-02-22 | Dicerna Pharmaceuticals, Inc. | Regulation of activity of rnai molecules |
| WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
| WO2025217569A1 (en) * | 2024-04-11 | 2025-10-16 | University Of Massachusetts | Conjugated chemically-modified dsrna during ex vivo perfusion of organs |
| WO2025259747A2 (en) * | 2024-06-12 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9745574B2 (en) * | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| CA3033368A1 (en) * | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| EP3517610A4 (en) * | 2016-09-23 | 2020-05-27 | National University Corporation Tokyo Medical and Dental University | THROUGH HETERODUPLEX NUCLEIC ACID THROUGH BLOOD BRAIN CABINET |
| MX2020011570A (es) * | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
| US20220228141A1 (en) * | 2020-11-23 | 2022-07-21 | University Of Massachusetts | Oligonucleotides for dgat2 modulation |
-
2021
- 2021-07-16 EP EP21843183.1A patent/EP4181932A4/en active Pending
- 2021-07-16 CN CN202180061336.7A patent/CN116600817A/zh active Pending
- 2021-07-16 CA CA3174068A patent/CA3174068A1/en active Pending
- 2021-07-16 AU AU2021308657A patent/AU2021308657A1/en active Pending
- 2021-07-16 US US17/377,632 patent/US20220042015A1/en active Pending
- 2021-07-16 WO PCT/US2021/041946 patent/WO2022016043A1/en not_active Ceased
- 2021-07-16 JP JP2023502828A patent/JP2023534951A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023534951A5 (https=) | ||
| JP2023550485A5 (https=) | ||
| JP2023522701A5 (https=) | ||
| JP2020536125A5 (https=) | ||
| US8148344B2 (en) | Compositions and methods for mediating RNAi in vivo | |
| ES2537568T3 (es) | Nuevos fármacos para inhibición de la expresión genética | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2022515193A5 (https=) | ||
| JP2023518268A5 (https=) | ||
| JP6038017B2 (ja) | 核酸を含む逆ミセル系及びその使用 | |
| JP2022528487A5 (https=) | ||
| JP2023518439A5 (https=) | ||
| JP7197463B2 (ja) | Ｓｍｎ２の調節のための化合物及び方法 | |
| JP2011517676A5 (https=) | ||
| WO2023022229A1 (ja) | モルホリノ核酸を含む修飾ヘテロ核酸 | |
| JP7560616B2 (ja) | 膜貫通型セリンプロテアーゼ６（ｔｍｐｒｓｓ６）発現を阻害するための組成物および方法 | |
| JP2023544413A5 (https=) | ||
| JP2022188237A (ja) | 転写プロセシングの調節のための化合物及び方法 | |
| EP3516062A1 (en) | Myostatin irna compositions and methods of use thereof | |
| JP2024522068A5 (https=) | ||
| JP2024528701A5 (https=) | ||
| JP2024509783A5 (https=) | ||
| JP2023530072A (ja) | Ｐｍｐ２２を調節するための化合物及び方法 | |
| JP2026506091A (ja) | ハンチンチン発現を調節するための対立遺伝子選択的化合物及び方法 | |
| WO2024173762A2 (en) | Compounds and methods for reducing app expression |